何川川，博士，副主任药师。2021年毕业于华中科技大学同济医学院药学院，获医学博士学位，2023年华中科技大学博士后出站，目前就职于嘉兴大学附属妇儿医院。

主持项目:

1.浙江省自然科学基金探索青年项目，ZCLQ24H3001，MnO₂包被脂质载体的构建及其提高阿霉素递送效率的研究，2024.01-2026.12，20万元，在研，主持

2.浙江省医药卫生科技计划项目（一般项目），2024KY1692，顺铂前药/MnO₂纳米粒用于化疗-化学动力协同抗肿瘤研究，2024.01-2026.12，5万元，在研，主持

代表论文（近五年，*表示共同通讯作者、#表示共同第一作者）：

1.Zhang X, He C*, He X, et al. HIF-1 inhibitor-based one-stone-two-birds strategy for enhanced cancer chemodynamic-immunotherapy. Journal of Controlled Release, 2023, 356(march):649-662.

2.He C^#, Zhang X^#, Sun Y, et al. A Solid Lipid Coated Calcium Peroxide Nanocarrier Enables Combined Cancer Chemo/Chemodynamic Therapy with O₂/H₂O₂ Self-Sufficiency. Acta Biomaterialia, 2021,122: 354-364.

3.He C^#, Zhang X^#, Yan R, et al. Enhancement of cisplatin efficacy by lipid-CaO₂ nanocarrier-mediated comprehensive modulation of the tumor microenvironment. [J]. Biomaterials Science, 2019, 7(10): 4260-4272.

4.He C^#, Zhang X^#, Xiang G. Nanoparticle Facilitated Delivery of Peroxides for Effective Cancer Treatments. Biomaterials Science, 2020, 8: 5574-5582

5.He C, Zhang Sh, Liu X. CaO₂ nanomedicines: a review of their emerging roles in cancer therapy. Nanotechnology, 2023, 34(48): 482002.

6.Zhang X^#, He C^#, Sun Y, et al. A Smart O₂-generating Nanocarrier Optimizes Drug Transportation Comprehensively for Improved Chemotherapy. Acta Pharmaceutica Sinica B, 2021,11:3608-3621.

7.Zhang X^#, He C^#, Yan R, et al. HIF-1 Dependent Reversal of Cisplatin Resistance via Anti-oxidative Nano Selenium for Effective Cancer Therapy[J]. Chemical Engineering Journal, 2020, 380: 122540.

8.Zhang X, He C, Liu X, et al. One-pot synthesis of a microporous organosilica-coated cisplatin nanoplatform for HIF-1-targeted combination cancer therapy. [J]. Theranostics, 2020, 10(7): 2918-2929.

9.Zhang X^#, He C^#, Chen Y, et al. Cooperative Chemodynamic/Starvation Cancer Therapy by Cyclic Reactions-mediated Self-Supply of H₂O₂ and O₂. Biomaterials, 2021, 275: 120987.

10.Zhang X^#, He C^#, Xiang G. Engineering Nanomedicines to Inhibit Hypoxia-Inducible Factor-1 for Innovative Cancer Therapy. Cancer Letters, 2022, 530: 110-127.

联系方式：Email: hechuanchuan@zjxu.edu.cn